Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Ocular Therapeutix Inc (NASDAQ: OCUL) closed the day trading at $11.71 down -3.62% from the previous closing price of $12.15. In other words, the price has decreased by -$3.62 from its previous closing price. On the day, 2.02 million shares were traded. OCUL stock price reached its highest trading level at $12.06 during the session, while it also had its lowest trading level at $11.605.
Ratios:
For a better understanding of OCUL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.78 and its Current Ratio is at 7.85. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.29.
Upgrades & Downgrades
In the most recent recommendation for this company, Chardan Capital Markets on September 15, 2025, initiated with a Buy rating and assigned the stock a target price of $21. On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.RBC Capital Mkts initiated its Outperform rating on March 18, 2025, with a $17 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 24 ’25 when Nayak Sanjay sold 1,878 shares for $12.04 per share. The transaction valued at 22,611 led to the insider holds 277,860 shares of the business.
Dugel Pravin sold 19,530 shares of OCUL for $235,141 on Nov 24 ’25. The insider now owns 3,157,960 shares after completing the transaction at $12.04 per share. On Nov 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,007 shares for $12.02 each. As a result, the insider received 36,144 and left with 191,433 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 2494785792 and an Enterprise Value of 2227021824. For the stock, the TTM Price-to-Sale (P/S) ratio is 44.73 while its Price-to-Book (P/B) ratio in mrq is 7.93. Its current Enterprise Value per Revenue stands at 39.923 whereas that against EBITDA is -8.569.
Stock Price History:
The Beta on a monthly basis for OCUL is 0.96, which has changed by 0.280295 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $13.85, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is 0.34%, while the 200-Day Moving Average is calculated to be 18.47%.
Shares Statistics:
Over the past 3-months, OCUL traded about 2.86M shares per day on average, while over the past 10 days, OCUL traded about 2931980 shares per day. A total of 213.05M shares are outstanding, with a floating share count of 186.81M. Insiders hold about 12.31% of the company’s shares, while institutions hold 79.18% stake in the company. Shares short for OCUL as of 1763078400 were 13173573 with a Short Ratio of 4.61, compared to 1760486400 on 13585178. Therefore, it implies a Short% of Shares Outstanding of 13173573 and a Short% of Float of 6.2.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Ocular Therapeutix Inc (OCUL) in the stock market.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.32 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$1.31 and -$1.49 for the fiscal current year, implying an average EPS of -$1.42. EPS for the following year is -$1.47, with 3.0 analysts recommending between -$1.3 and -$1.56.
Revenue Estimates
12 analysts predict $16.28M in revenue for. The current quarter. It ranges from a high estimate of $29.1M to a low estimate of $11.6M. As of. The current estimate, Ocular Therapeutix Inc’s year-ago sales were $17.08MFor the next quarter, 12 analysts are estimating revenue of $14.22M. There is a high estimate of $18.1M for the next quarter, whereas the lowest estimate is $11.5M.
A total of 12 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $67.8M, while the lowest revenue estimate was $50.3M, resulting in an average revenue estimate of $54.97M. In the same quarter a year ago, actual revenue was $63.72MBased on 12 analysts’ estimates, the company’s revenue will be $63.85M in the next fiscal year. The high estimate is $82.9M and the low estimate is $52.3M.
